Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Avelumab with Chemoradiation in Muscle Invasive Bladder Cancer
NCT03617913Phase 2Completed
- Sponsor
- Mayo Clinic
- Start
- Sep 2018
- Primary completion
- Nov 2019
- Modality
- Immune Checkpoint Inhibitors, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of avelumab in bladder cancer, sponsored by Mayo Clinic. Primary endpoint: Proportion of Participants With Complete Response at 6 months. Started Sep 2018; status: completed.
02
Drugs
avelumab
03
Conditions
bladder cancer
Beyond the preview
Go deeper on NCT03617913.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03617913.